Management of Esophagogastric Junction Cancer

Esophagogastric junction cancer (EGJ) is a challenging disease to manage and requires multidisciplinary management with collaboration across medical, surgical, and radiation oncology specialties. EGJ has a poor prognosis due to its aggressive behavior, late presentation, and associated comorbidities. There are several reasons why EGJ has a poor prognosis, including its tendency to spread rapidly, the difficulty of detecting it early on when treatment is more effective, and the challenges associated with treating tumors located in areas that are difficult to access. Furthermore, EGJ also presents unique clinical challenges due to its diverse histologic subtypes that exhibit different biological behaviors and responses to treatment. In addition, the management of EGJ requires a personalized approach based on an individual patient’s history and physiological status. This approach should also consider the patient’s comorbidities, as many patients with EGJ have concurrent medical conditions that complicate their management and increase the risk of morbidity and mortality associated with treatment. Thus, the management of EGJ is complex and requires a collaborative effort between different medical disciplines to optimize patient outcomes while minimizing treatment-related morbidity. Moreover, the optimal management of EGJ depends on various factors, including tumor location, histologic subtype, and patient-specific characteristics. Surgical resection remains the primary curative treatment option for EGJ, along with perioperative chemotherapy or chemoradiation.